MolecuLight Inc. Ontario

United States Patent and Trademark Office Cancels All Claims of Swift Medical's Patent

worldwide, MolecuLight's i:X and DX technologies are integrated into standard clinical practice by leading wound care facilities globally.

About MolecuLight Inc.

MolecuLight Inc. is a privately-owned medical imaging company that has developed and is commercializing its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, which includes the MolecuLight i:X® and DX™ fluorescence imaging systems and their accessories, are point-of-care handheld imaging devices for the real-time detection and localization of bacterial load in wounds and digital wound measurement. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway which includes two CPT® codes for physician work to perform "fluorescence imaging for bacterial presence, location, and load" and facility payment for Hospital Outpatient Department (HOPD) and Ambulatory Surgical Center (ASC) settings through an Ambulatory Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology for other global markets with relevant unmet needs in food safety, consumer cosmetics and other key industrial markets.

Photo - https://mma.prnewswire.com/media/2282027/MolecuLight_United_States_Patent_and_Trademark_Office__USPTO__Ca.jpg

View original content:https://www.prnewswire.co.uk/news-releases/united-states-patent-and-trademark-office-uspto-cancels-all-claims-of-swift-medicals-patent-301993938.html